Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2011

View Archived Issues

Ampio and Daewoong enter urology drug agreement in South Korea

Diffusion tensor imaging detects cerebral anomalies in patients with Asperger's syndrome

Novel PET tracer may help guide development of fatty-acid amide hydrolase inhibitors

MedImmune presents new safety data on MEDI-573 in breast cancer

Synthesis and preclinical testing of novel histamine H3 receptor antagonists described

Repros completes enrollment in three ongoing Androxal trials

First-in-human study supports feasibility of intraoperative tumor-specific fluorescence imaging

Novel susceptibility gene for major depression identified

Randomized, double-blind trial assesses LY-2189265 as monotherapy for type 2 diabetes

BioLineRx reports preliminary first-in-human data on BL-1021

Nanobiotix's lead product enters clinic

Compugen validates immunomodulating fusion proteins in in vivo models of autoimmune diseases

GlaxoSmithKline discloses new fatty acid synthase inhibitors

Spanish research center prepares novel protein kinase inhibitors

Viamet Pharmaceuticals begins first-in-human trial of VT-1161

Novartis synthesizes novel cyclin-dependent kinase inhibitors

Rare Disease Therapeutics selects distributor for Anascorp

Avila Therapeutics advances phase Ib AVL-292 study

ProFibrix completes recruitment in two phase II Fibrocaps trials

Scientists at Medivation claim new neurotransmitter receptor modulators

Oncothyreon obtains license to anticancer agents from Sanford-Burnham Medical Research Institute

Arrien gathers financing to support advancement of small-molecule protein kinase inhibitors

Eisai enters collaboration with SFJ to conduct phase III E-7080 trials

Thrasos Innovation advances THR-184 to clinic

Astellas Pharma set to launch Betanis in Japan

Vibativ approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...